A Retrospective Study of First-Line Therapy Involving Immune Checkpoint Inhibitors in Patients With Poor Risk Metastatic Renal Cell Carcinoma

PurposePatients with International Metastatic RCC Database Consortium (IMDC) poor risk metastatic renal cell carcinoma (mRCC) rarely respond to first-line tyrosine kinase inhibitors (TKIs) including sunitinib, and carries a very poor prognosis. In recent years, combination therapy involving immune c...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Hyunji Jo, Joohyun Hong, Hongsik Kim, Hye Ryeon Kim, Ghee Young Kwon, Kyung A. Kang, Sung Yoon Park, Chan Kyo Kim, Byung Kwan Park, Jae Hoon Chung, Wan Song, Minyong Kang, Hyun Hwan Sung, Hwang Gyun Jeon, Byong Chang Jeong, Seong Il Seo, Seong Soo Jeon, Hyun Moo Lee, Se Hoon Park
Médium: Artigo
Jazyk:Inglês
Vydáno: Frontiers Media S.A. 2022-04-01
Edice:Frontiers in Oncology
Témata:
immunotherapy
immune checkpoint inhibitors
renal cell carcinoma
IMDC poor-risk
overall survival
sunitinib
On-line přístup:https://www.frontiersin.org/articles/10.3389/fonc.2022.874385/full
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky